Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Better Exit for Private Biotechs: M&A

This article was originally published in Start Up

Executive Summary

Does the recent flurry of acquisitions of private biotech companies by pharma companies represent a new and continuing trend? Yes--and a real change in thinking at Big Pharma and among VCs.

You may also be interested in...



Pfizer/Angiosyn: Building Biotechs for Device-style Early M&A

Pfizer's acquisition of privately-held Angiosyn is basically a milestones-and-royalty-based licensing deal for the biotech's preclinical non-VEGF targeting AMD candidate. Angiosyn was designed for early M&A, much like most medical device firms of the past ten years, and this risk-sharing agreement with Pfizer may imply a new, leaner model for biotech company building.

The Buzz at JP Morgan--Biopharma: New Models Wanted

Perhaps the loudest message from the biopharmaceutical side of the JP Morgan conference was: "Change the Big Pharma model." The theme was pervasive-in discussions of the most interesting products; among the biotechs; indeed in the Big Pharma presentations themselves.

The Biotech Investment Act

The Homeland Investment Act will allow Big Pharma to bring into the US a huge horde of foreign earnings at very attractive tax rates. Given the pipeline drought, some of that money is going to go to biotechs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel